Logo image of PROF

PROFOUND MEDICAL CORP (PROF) Stock Price, Quote, News and Overview

NASDAQ:PROF - Nasdaq - CA74319B5027 - Common Stock - Currency: USD

6.15  +0.15 (+2.5%)

PROF Quote, Performance and Key Statistics

PROFOUND MEDICAL CORP

NASDAQ:PROF (6/26/2025, 8:20:21 PM)

6.15

+0.15 (+2.5%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High11.42
52 Week Low3.9
Market Cap184.81M
Shares30.05M
Float24.78M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO09-24 2014-09-24


PROF short term performance overview.The bars show the price performance of PROF in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

PROF long term performance overview.The bars show the price performance of PROF in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of PROF is 6.15 USD. In the past month the price increased by 17.37%. In the past year, price decreased by -26.7%.

PROFOUND MEDICAL CORP / PROF Daily stock chart

PROF Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.96 232.56B
ISRG INTUITIVE SURGICAL INC 69.92 191.46B
BSX BOSTON SCIENTIFIC CORP 38.73 154.72B
SYK STRYKER CORP 31.16 149.20B
MDT MEDTRONIC PLC 15.67 110.53B
BDX BECTON DICKINSON AND CO 12.06 48.72B
EW EDWARDS LIFESCIENCES CORP 29.67 45.26B
IDXX IDEXX LABORATORIES INC 46.3 42.77B
RMD RESMED INC 28.22 37.57B
GEHC GE HEALTHCARE TECHNOLOGY 16.27 34.28B
DXCM DEXCOM INC 51.54 33.35B
STE STERIS PLC 25.54 23.44B

About PROF

Company Profile

PROF logo image Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Company Info

PROFOUND MEDICAL CORP

2400 Skymark Ave Unit 6

Mississauga ONTARIO L4W 5K5 CA

CEO: Arun Menawat

Employees: 142

PROF Company Website

PROF Investor Relations

Phone: 16474761350

PROFOUND MEDICAL CORP / PROF FAQ

What is the stock price of PROFOUND MEDICAL CORP today?

The current stock price of PROF is 6.15 USD. The price increased by 2.5% in the last trading session.


What is the ticker symbol for PROFOUND MEDICAL CORP stock?

The exchange symbol of PROFOUND MEDICAL CORP is PROF and it is listed on the Nasdaq exchange.


On which exchange is PROF stock listed?

PROF stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PROFOUND MEDICAL CORP stock?

6 analysts have analysed PROF and the average price target is 8.47 USD. This implies a price increase of 37.65% is expected in the next year compared to the current price of 6.15. Check the PROFOUND MEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PROFOUND MEDICAL CORP worth?

PROFOUND MEDICAL CORP (PROF) has a market capitalization of 184.81M USD. This makes PROF a Micro Cap stock.


How many employees does PROFOUND MEDICAL CORP have?

PROFOUND MEDICAL CORP (PROF) currently has 142 employees.


What are the support and resistance levels for PROFOUND MEDICAL CORP (PROF) stock?

PROFOUND MEDICAL CORP (PROF) has a support level at 6.14 and a resistance level at 6.55. Check the full technical report for a detailed analysis of PROF support and resistance levels.


Is PROFOUND MEDICAL CORP (PROF) expected to grow?

The Revenue of PROFOUND MEDICAL CORP (PROF) is expected to grow by 62.2% in the next year. Check the estimates tab for more information on the PROF EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PROFOUND MEDICAL CORP (PROF) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROFOUND MEDICAL CORP (PROF) stock pay dividends?

PROF does not pay a dividend.


When does PROFOUND MEDICAL CORP (PROF) report earnings?

PROFOUND MEDICAL CORP (PROF) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of PROFOUND MEDICAL CORP (PROF)?

PROFOUND MEDICAL CORP (PROF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.22).


What is the Short Interest ratio of PROFOUND MEDICAL CORP (PROF) stock?

The outstanding short interest for PROFOUND MEDICAL CORP (PROF) is 2.16% of its float. Check the ownership tab for more information on the PROF short interest.


PROF Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to PROF. When comparing the yearly performance of all stocks, PROF is a bad performer in the overall market: 82.01% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PROF Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to PROF. While PROF seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PROF Financial Highlights

Over the last trailing twelve months PROF reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS increased by 5.43% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -52.5%
ROE -62.92%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-38.46%
Sales Q2Q%37.23%
EPS 1Y (TTM)5.43%
Revenue 1Y (TTM)63.64%

PROF Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to PROF. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of -0.1% and a revenue growth 62.2% for PROF


Ownership
Inst Owners47.21%
Ins Owners17.51%
Short Float %2.16%
Short Ratio6.61
Analysts
Analysts80
Price Target8.47 (37.72%)
EPS Next Y-0.1%
Revenue Next Year62.2%